Open Nav

Miromatrix Medical Inc.

  • Jeff Ross, Miromatrix Medical Inc.

Identify Strategic Partners and Potential Investors

  • Date:Thursday, October 18
  • Time:2:45 PM - 3:00 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Miromatrix is a leading regenerative medicine company bioengineering transplantable organs including livers, kidneys and hearts based on its patented perfusion decellularization and recellularization technology, with collaborators including The Mayo Clinic, Mount Sinai Hospital, and Texas Heart Institute. In addition to whole organ development, Miromatrix has successfully developed, manufactured and commercialized a series of porcine organ-derived biological products. MIROMESH®, is the only liver-derived biologic mesh for soft tissue reinforcement and MIRODERM®, is the only liver-derived wound care product and a recent case-series published in WOUNDS® demonstrated its ability to successfully treat diabetic foot ulcers that had previous failed other advanced biologics. Miromatrix is leveraging these successes with our recellularization technology to fully address the transplantable organ shortage.
  • Company
  • Company HQ City:Eden Prairie
  • Company HQ Country:United States
  • Company HQ State:Minnesota                  
  • CEO/Top Company Official:Jeff Ross, Ph.D.
  • Year Founded:2009
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development :Bioengineered Liver
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:Miromatrix is targeting the initiation of human clinical studies for its transplantable liver program as early Q4-2020, with a bioengineered kidney to follow shortly after. In addition to whole organ development, Miromatrix completed enrollment in their post market multicenter clinical study (Miromatrix Biological Mesh for Hiatal Hernia Repair) to measure 1 and 2-year recurrence rates of hiatal hernia repaired with MIROMESH requiring reintervention in the summer of 2016. One-year data was recently reported and the complete study report is expected to be released in the fall of 2018. Miromatrix is actively enrolling in a second clinical study (MIRODERM H2H DFU Study) to demonstrated the efficacy of MIRODERM to heal diabetic foot ulcers that had previously failed other advanced biologic therapy. The study is scheduled to complete enrollment in early 2018 and report outcomes in the fall of 2018.
  • Size of Last Investment Round:$10,000,000 USD
  • Total Amount Raised to Date, In All Rounds:$35,000,000 USD
Jeff Ross
Miromatrix Medical Inc.